Major Events - Yunzhisheng (09678) secured a regional medical cooperation contract worth over 20 million [1] - Kelun-Biotech (06990) received breakthrough therapy designation from NMPA for TROP2 ADC drug in combination with pembrolizumab for treating PD-L1 positive locally advanced or metastatic non-small cell lung cancer [1] - InSilico Medicine (03696) entered into an 8.88 billion USD multi-year collaboration for anti-tumor drug development with Sihuiya [1] - Hutchison China MediTech (00013) is conducting a Phase III study on surufatinib combined with camrelizumab for first-line treatment of pancreatic ductal adenocarcinoma [1] - Ascletis Pharma-B (01672) announced FDA approval for IND of ASC30 in a 13-week Phase II study in diabetic patients [1] - Foryou Medical (01696) received quality standard inspection approval for its reauthorized injectable botulinum toxin from the Chinese National Medical Products Administration [1] - CanSino Biologics (06185) obtained clinical trial approval in China for its 24-valent pneumococcal polysaccharide conjugate vaccine [1] - Stone Group (02005) received drug production registration approval for perindopril and amlodipine tablets [1] - Sunny Optical Technology (02382) proposed to spin off its automotive optical business for independent listing on the Hong Kong Stock Exchange [1] - Dongyang Sunshine Pharmaceutical (06887) completed the first patient enrollment for HECN30227 in China [1] - Haitong International's subsidiary plans to sell 100% equity of Guohua Machinery for 342 million [1] - Yuexiu Property (00123) subsidiary intends to sell 73.74% actual equity in Hangzhou Yueyun [1] - CIMC Group (02039) subsidiary CIMC Shilianda plans to introduce strategic investors through capital increase and transfer of a small number of old shares [1] Operating Performance - Chifeng Jilong Gold Mining (06693) expects annual net profit attributable to shareholders to be approximately 3 billion to 3.2 billion, an increase of about 70% to 81% year-on-year [2] - Corning Hospital (02120) anticipates outpatient visits to reach approximately 720,200 in 2025, a year-on-year increase of 29% [2] - Seres (09927) reported total vehicle sales of 63,700 units in December, a year-on-year increase of 53.54% [2] - Xiehe New Energy (00182) reported an equity power generation of 790.32 GWh in December [2] - Country Garden (02007) reported contract sales amounting to approximately 2.69 billion attributable to shareholders in December [2]

Group 1 - Fulin Precision's subsidiary plans to invest 6 billion yuan to build a high-end lithium iron phosphate project with an annual production capacity of 500,000 tons [11] - Feiwo Technology has completed the acquisition of 60% of Xinsai Aerospace, focusing on metal 3D printing services for commercial aerospace [2] - Zhongcai Technology expects a net profit increase of 73.79% to 118.64% in 2025 [30] Group 2 - Hengrui Medicine has received approval for clinical trials of HRS9531 injection in combination with HRS-5817 injection for treating obesity [2] - Deyun Co. announced that its actual controller has been arrested for illegal public deposit collection, but the company's operations remain normal [3] - Hengshi Technology's control is set to change as it enters a strategic cooperation agreement with New Base Information Technology Group [4] Group 3 - Zhejiang Mining plans to acquire 100% of Alaigyr Company, which holds core assets in lead-silver mines [5][6] - Guizhou Tire intends to invest in a project in Morocco to produce 6 million semi-steel radial tires annually, with a total investment of 299 million USD [7] - Dongfang Zircon plans to invest in a project to produce 10,000 tons of high-purity composite zircon oxide for new energy batteries [8] Group 4 - Xingsheng Group has received a project designation notice from a North American electric vehicle manufacturer, with a total sales amount of approximately 7.8 billion yuan [18] - Jin Di Co. plans to acquire a 3.36% stake in Baoshilai New Materials Technology for 21.6 million yuan [10] - Huayi Technology has signed a strategic cooperation agreement with Fujian Fuyou University to enhance research and development in alloy materials [6] Group 5 - Juxing Technology expects a net profit increase of 5% to 20% in 2025 [23] - Huayou Cobalt anticipates a net profit increase of 40.8% to 55.24% in 2025 [24] - Chifeng Gold expects a net profit increase of approximately 70% to 81% in 2025 [25]

文｜新能源观 众所周知，车企盈利的左右手是"以量取胜"和"以质见长"，前者如比亚迪，后者如赛力斯。 2025年，比亚迪总共销售了460万辆，同比增长7.73%，销量基本盘海洋网和王朝网合计贡献了407.5万辆，占总销量的88%。赛力斯问界汽车2025年新车交 付总计突破42万辆，同比增长9.25%。 图/2025年比亚 迪销量 而从两家车企公布的最新一期财报来看，比亚迪2025年前三季度全球累计销量326万辆，同比增长18.64%；营收达5662.7亿元，同比增长13%；净利润为 233.33亿元，同比下降7.55%。 | 产品名称 | | | 产量 | | | | --- | --- | --- | --- | --- | --- | | | 本月 | 本月同比 | 本年累计 | 累计同比 | 本月 | | 新能源汽车 | 45, 453 | 21. 48% | 310, 084 | -3. 49% | 44, 678 | | 其中:赛力斯汽车 | 42, 459 | 16. 88% | 281, 822 | -5.44% | 41.249 | | 其他车型 | 3, 794 | -40. 29% | 35 ...

智通财经APP讯，赛力斯(601127.SH)发布公告，公司2025年12月新能源汽车产量55970辆，同比增长 67.06%;新能源汽车销量60981辆，同比增长63.40%。 ...

赛力斯（601127）(601127.SH)发布公告，公司2025年12月新能源汽车产量55970辆，同比增长67.06%;新 能源汽车销量60981辆，同比增长63.40%。 ...

其中，问界2025年12月交付新车超5.7万辆，刷新单月交付纪录；2025全年累计交付新车突破42万辆， 领跑高端新能源汽车市场。 1月5日晚间，赛力斯(601127)发布2025年12月产销快报。当月，赛力斯新能源汽车销量60981辆，同比 增长63.40%，已连续三个月单月销量突破5万大关；2025年全年累计销量达472269辆，同比增长 10.63%，创下年度销量新里程碑。 资本层面，赛力斯同样实现重要跨越。2025年11月，赛力斯成功登陆港股，成为首家实现"A+H"两地上 市的豪华新能源车企。这一里程碑事件，不仅为赛力斯未来全球资源整合、技术研发协同、品牌价值提 升开辟更广阔空间，更将向国际资本市场展示中国新能源车企在高端市场的核心竞争力，助力"中国智 造"在全球高端新能源汽车领域进一步突破。同期，公司首次入选中证A100指数，进一步印证了其在A 股新能源汽车领域的龙头地位。 展望未来，赛力斯表示将继续以用户为中心、以技术为引擎，在智能电动汽车的赛道上稳步前行，致力 于打造更具竞争力与影响力的全球新能源汽车产品，引领行业迈向高质量发展新阶段。 （文章来源：证券时报网） 2025年，赛力斯坚持"软件定义 ...

2025年1-12月，该公司汽车产量合计51.81万辆，同比增加4.37%;汽车销量合计51.69万辆，同比增加 3.99%。 智通财经APP讯，赛力斯(09927)发布公告，该公司2025年12月份汽车产量合计5.78万辆，同比增加 46.6%;汽车销量合计6.37万辆，同比增加53.54%。 ...

赛力斯（601127）(09927)发布公告，该公司2025年12月份汽车产量合计5.78万辆，同比增加46.6%;汽车 销量合计6.37万辆，同比增加53.54%。 2025年1-12月，该公司汽车产量合计51.81万辆，同比增加4.37%;汽车销量合计51.69万辆，同比增加 3.99%。 ...

赛力斯2025年12月产销快报解读核心要点 一、12月产销数据 新能源汽车：产量47.37万辆（+10.31%），销量47.23万辆（+10.63%） 其中赛力斯汽车：产销均超43万辆（+10.52%） 合计产量51.81万辆（+4.37%），销量51.69万辆（+3.99%） 三、结构变化 其他车型持续下滑，12月产销分别为1,812辆和2,732辆，同比降幅超30%风险提示及免责条款市场有风 险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。 用户应考虑本文中的任何意见、观点或结论是否符合其特定状况。据此投资，责任自负。 新能源汽车：产量5.60万辆（+67.06%），销量6.10万辆（+63.40%） 其中赛力斯汽车：产量4.86万辆（+89.76%），销量5.37万辆（+77.99%） 合计产量5.78万辆（+46.60%），销量6.37万辆（+53.54%） 二、2025年全年累计 ...

1月5日，赛力斯发布2025年12月产销快报。数据显示，赛力斯新能源汽车12月销量60,981辆，同比增长 63.40%，已连续三个月单月销量突破5万大关；1-12月累计销量达472,269辆，同比增长10.63%，迎来年 度销量新里程碑。问界2025年12月交付新车超5.7万辆，创单月交付新纪录；2025全年累计交付新车突 破42万辆，领跑高端新能源汽车市场。 2025年，赛力斯坚持"软件定义汽车"的技术路线和"用户定义汽车"的市场导向，持续深耕高端化、智能 化、绿色化发展路径。通过不断完善产品矩阵，已形成问界M5、M7、M9、M8四大产品序列，全面覆 盖豪华细分市场。 截至目前，问界累计交付新车超97万辆，持续刷新中国新能源市场交付速度。其中，问界M9累计20个 月稳居50万元级以上豪华SUV销量第一，上市以来累计交付超26万辆，成为中国高端豪华车市场的代表 车型；问界M8上市8个月累计交付超15万辆，迅速占领40万元级高端SUV市场；问界M7累计交付超37 万辆，全新问界M7在2025年9月正式上市后，凭借全方位进阶的产品力，成为30万元级SUV的价值之 选。 技术创新是企业发展之本。赛力斯始终立足技术 ...